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DETERMINING THE COST OF A BLEEDING-RELATED EPISODE IN PRIMARY 
ADULT CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN THE UNITED STATES  
Northridge K1, Danese M1, Deuson R2 
1Outcomes Insights, Inc., Westlake Village, CA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA  
OBJECTIVES: Chronic immune thrombocytopenia (ITP) is characterized by low 
platelet counts and an increased risk of bleeding-related episodes (BRE). The 
study purpose was to estimate the cost of BREs in the US. METHODS: A BRE 
includes rescue medication use, a bleeding event, or both. The BRE endpoint was 
tested in two 6-month placebo-controlled trials for romiplostim in adult patients 
with ITP (median baseline platelet counts of 16 x 109/L; 64% received ≥3 
treatments prior to baseline). Results from pooled analyses across studies and 
treatment arms showed that 63% of BREs were mild (outpatient management 
without immunoglobulins), 31% were moderate (outpatient management with 
immunoglobulins), and 6% were severe (inpatient management with 
immunoglobulins). The annual BRE rate per patient was 1.80 for patients with 
platelets ≥50 x 109/L at the time of BRE and 7.33 for patients with platelets <50 x 
109/L. BRE costs were estimated using 2012 Medicare rates for office visits, oral 
steroids, immunoglobulins (IVIg dose of 2 g/kg per episode, and Anti-D dose of 50 
mcg/kg in 25% of non-splenectomized patients), and hospitalization for 
intracranial hemorrhage, gastrointestinal hemorrhage, and coagulation 
disorders. RESULTS: The estimated costs of a mild, moderate, and severe BRE 
were $112, $10,737, and $21,871; with a weighted average BRE cost of $4,703, and 
an average annual cost of $8,465 (platelets ≥50 x 109/L) and $34,473 (platelets <50 
x 109/L). In sensitivity analyses, the cost of immunoglobulins was the most 
important variable; a ±50% change in cost (or dose) resulted in ±41% change in 
the weighted average BRE cost ($2,778 to $6,628). CONCLUSIONS: Bleeding events 
and rescue medications (particularly immunoglobulins) represent a significant 
cost of treatment, particularly in ITP patients with platelet counts lower than <50 
x 109/L.  
 
PSY37  
COST IMPACT OF DEPOFOAM BUPIVACAINE FOR THE MANAGEMENT OF POST-
SURGICAL PAIN  
Ektare V1, Scranton R2, Botteman MF1 
1Pharmerit International, Bethesda, MD, USA, 2Pacira Pharmaceuticals, Parsippany, NJ, USA  
OBJECTIVES: Clinical trials in soft tissue surgery with Depofoam® bupivacaine 
(DB) have shown that a single injection into the surgical site provides 
postsurgical pain control for up to 72 hours while reducing the need for opioids. 
This study extrapolates via a simplified decision tree the economic impact of DB 
versus bupivacaine HCl (BH) in patients undergoing colectomy and 
cholecystectomy. METHODS: This simple model combined data from a claims 
database analysis with literature. The incidence of opioid use (92%) and risk of 
ICD-9 diagnosis-coded opioid-related adverse events (ORAEs) (16.32%) for the BH 
group were estimated via retrospective analysis of the Premier hospital database. 
The incidence rates of opioid use (68%) and ORAEs (1.86%) in the DB group were 
based on the relative reduction between DB and BH observed in a 
hemorrhoidectomy trial. The excess cost per patient with ORAE ($4,707) was 
estimated from Premier. DB and BH drug acquisition costs, opioid costs 
(including inpatient pharmacy, administration, errors and outpatient pharmacy) 
were literature based. Analyses were conducted in 378 subgroups defined by 
surgery types (colectomy and cholecystectomy) and demographics.  
RESULTS: Compared to BH, the use of DB is projected to result in an increase in 
analgesia drug acquisition cost of $249/patient. This was offset by expected 
reductions in opioids (-$95/patient) and ORAE (-$680/patient) costs, resulting in 
net cost savings of $526/patient overall. DB resulted in modeled costs savings in 
all but one of the 378 subgroups. These ranged from cost savings of 
$1,633/patient in the “open cholecystectomy/admission source trauma” 
subgroup to a cost increase of $28/patient in the “cholecystectomy/age  
18-30” subgroup. CONCLUSIONS: As a result of better pain management and 
reduced opioids usage, the use of DB (v. BH) at the time of 
colectomy/cholecystectomy is modeled to be cost saving overall and in 99.7% of 
subgroups considered.  
 
PSY38  
FIRST-LINE USE OF CALCIPOTRIENE/BETAMETHASONE DIPROPIONATE 
COMBINATION PRODUCTS FOR THE TREATMENT OF PLAQUE PSORIASIS IS 
ASSOCIATED WITH LOWER HEALTH CARE UTILIZATION AND COST  
Feldman SR1, Levi E2, Pathak P3, Kakatkar S3, Blakrishnan R4 
1Wake Forest University, Winston-Salem, NC, USA, 2LEO Pharma Inc., Parsippany, NJ, USA, 
3Outcomes Inc., Dulles, VA, USA, 4University of Michigan and Outcomes Inc., Dulles, VA, USA  
OBJECTIVES: Calcipotriene/betamethasone dipropionate combination topical 
products are an established treatment for patients with plaque psoriasis. In 
appropriate patients, using the combination products as first-line therapy after 
the psoriasis diagnosis might be beneficial. This study investigated whether such 
use might lower the cost impact on health care budgets. METHODS: A 
retrospective study using Thomson Reuters MarketScan® national claims data 
from 2006-2011 was performed to identify patients who received psoriasis 
medications following a psoriasis diagnosis (ICD-9 code 696.1x). Patients were 
continuously enrolled during 1-year pre- and post-index date periods. The 2 
study cohorts were cohort A (patients treated with calcipotriene/betamethasone 
dipropionate combination products immediately post-diagnosis) and cohort B 
(patients treated with any other topical psoriasis medication immediately post-
diagnosis). The frequency of office visits and total health care costs (includes 
pharmacy costs and costs of inpatient and outpatient services) during the 1-year 
post-index period were assessed. Multiple regression analyses adjusting for 
baseline demographic and clinical covariates, including a proxy for psoriasis 
severity, were performed. RESULTS: In total, 16,977 patients were identified in 
the 2 cohorts based on the topical medication prescribed (cohort A = 7307; cohort 
B = 9670). During the 1-year follow-up period, mean (± SD) total and psoriasis-
related office visits were significantly lower in cohort A (13.36 ± 14.39; 2.79 ± 7.60) 
than cohort B (16.08 ± 16.68; 4.25 ± 10.23) (both P<.001). Mean total health care 
costs were less for cohort A ($7785.80 ± $15,255.60; median = $3411) than cohort B 
($11,757.20 ± $19,747.60; median = $5595.80) (P<.001). In a generalized linear 
model adjusted for baseline covariates, cohort A had significantly lower costs 
than cohort B (β ± SE = 0.041 ± 0.017; P=.02). CONCLUSIONS: First-line treatment 
with calcipotriene/betamethasone dipropionate combination products after 
psoriasis diagnosis was associated with fewer office visits and lower total health 
care costs.  
 
PSY39  
COSTS ASSOCIATED WITH INTRAVENOUS PATIENT CONTROLLED ANALGESIA 
(IV-PCA) IN US HOSPITALS  
Schechter L1, Harshaw Q2, Frye CB3, Ernst FR4, Krukas M4, Shillington A2 
1Thomas Jefferson University Hospital, Philadelphia, PA, USA, 2EPI-Q Inc., Oak Brook, IL, USA, 
3EPI-Q, Inc., Oak Brook, IL, USA, 4Premier healthcare alliance, Charlotte, NC, USA  
OBJECTIVES: Resource evaluation of intravenous patient-controlled analgesia to 
date has focused primarily on nursing or pharmacy staff time. Some have 
quantified IV-PCA related error costs but little data exists on estimated total 
costs from the hospital provider’s perspective. The objective of this study is to 
model IV‐PCA therapy costs in an inpatient, postoperative population. 
METHODS: Cost model data were obtained by 1) survey of 140 hospital pharmacy 
directors (drug, IV-PCA pump-related and non-drug supply costs), 2) Premier 
hospital research database analysis of 7 million surgical discharges from 2008-
2011 (IV-PCA- related complications and cost, and length of stay adjusting for 
demographics, comorbidity and procedures) and 3) by systematic literature 
review (nursing/pharmacy staff time, IV-PCA related errors, delineation of IV-
PCA-related tasks). Sensitivity analyses were conducted. RESULTS: Mean 
duration of IV-PCA in the Premier database per post-surgical inpatient was 
1.7days. The mean cost per day of IV-PCA was $305.37 on day 1, and $264.13 on 
day 2. Individual mean costs per IV-PCA day included pharmacy drug, 
$19.66/day; nursing labor, $38.13 on day 1, and $17.57 on day 2; pharmacy labor, 
$13.17/day; pump cost, $5.24/day; error-related costs, $19.71/day; and non-drug 
disposables, $21.56 on day 1, and $0.88 on day 2. Costs of complications related 
to IV-PCA (DVT, PE, post-op pneumonia occurred in 2.1% of IV-PCA patients vs. 
1.6% of non-IV-PCA patients) added $187.58 per IV-PCA day, with cost adjusted 
for baseline demographics and surgical procedure. In addition to per IV-PCA day 
costs, analyses of Premier data indicate IV-PCA patients had a statistically 
significant extended length of stay adjusting for baseline demographics and 
surgical procedures (mean LOS IV-PCA 4.53 [95% CI 4.41-4.66], LOS non IV-PCA 
4.24 [95% CI 4.12-4.35]). CONCLUSIONS: IV-PCA, while a mainstay of post of post-
operative pain management, is costly. Less resource intensive IV-PCA with fewer 
associated complications could be beneficial to hospitals.  
 
PSY40  
EXPENDITURE AND EFFECTIVENESS OF TREATMENT OPTIONS IN CHRONIC 
MYELOID LEUKEMIA PATIENTS WHO FAILED IN THE FIRST-LINE IMATINIB 
TREATMENT  
Chen W1, Zhu JJ2 
1Fudan University, Shanghai, China, 2School of Public Health, Fudan University, Shanghai, China  
OBJECTIVES: To compare medical expenditure and effectiveness of different 
therapies in chronic myeloid leukemia patients who failed in the first-line 
imatinib treatment. METHODS: A structured questionnaire was designed to 
collect the detailed data from 28 clinical experts, including treatment 
alternatives for the patients with chronic myeloid leukemia who failed in first-
line imatinib treatment, and medical service utilization, medical expenditure 
and effectiveness of different therapies (nilotinib, imatinib dose-escalation and 
allo-SCT). RESULTS: The choices of the second-line therapies for the patients 
who failed in the first-line imatinib treatment included nilotinib, imatinib dose-
escalation and allo-SCT. The cytogenetic response of nilotinib was always higher 
than imatinib dose escalation. After 1-1.5 years, the cumulative cytogenetic 
response rate of nilotinib could be as high as 80%, which is significantly higher 
than that of imatinib. The most common adverse effects of nilotinib included 
hematologic toxicities (anemia, thrombocytopenia and neutropenia), 
hyperbilirubinemia, prolongation of QT interval, liver injuries, skin alterations, 
edema, jaundice and gastrointestinal disturbance. In parallel, bone marrow 
suppression is the most frequent toxicities of imatinib dose escalation 
treatment. Other non-hematologic adverse effects were similar, included fluid 
retention, gastrointestinal disturbance, muscular cramp and bone and joint pain. 
The expenditure of nilotinib and dose-escalated imatinib therapies was quite 
similar, and significantly higher than that of first-line imatinib treatment. 
CONCLUSIONS: It is strongly suggested that nilotinib treatment should be 
considered as standard treatment of imatinib-failed patients in China.  
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ESTIMATING THE COST-EFFECTIVENESS OF BELIMUMAB VERSUS STANDARD 
CARE FOR SLE PATIENTS IN HONG KONG  
Lee KKC1, Azmi S2, Wu DBC3, Goh A2 
1Monash University Sunway Campus, Selangor, Malaysia, 2Azmi Burhani Consulting Sdn Bhd, 
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OBJECTIVES: Systemic Lupus Erythematosus(SLE) is a debilitating illness caused 
by an autoimmune disorder that can affect many organs of the body, including 
skin, joints, kidneys, lungs and the nervous system. Therapy with steroids and 
immunosuppressives can lead to further organ damage. Belimumab is a fully 
human monoclonal antibody that has been found to be effective against SLE in 
trials. The current study assesses the cost-effectiveness of belimumab in Hong 
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Kong SLE patients compared to standard care. METHODS: A lifetime 
microsimulation model was adapted with epidemiological and cost data from 
Hong Kong. The model compares the use of belimumab against standard care 
and incorporates the BLISS-52 and BLISS-76 trial data for the short term 
outcomes within one year, while long-term outcomes were based on a natural 
history model developed using the Johns Hopkins Lupus registry. The natural 
history model describes the relationship between disease activity and other 
covariates on the risk of dying and developing organ damage. Data available 
from the SLE population in Hong Kong was used as input in the modified model. 
The analysis was performed from a Hong Kong health-care perspective. In the 
base case, cost and effectiveness were discounted to the year of analysis at 5% 
p.a. RESULTS: The base case analysis showed that compared to standard care, 
treatment with belimumab increased life expectancy by 0.80 (2.77 undiscounted) 
and QALY by 0.60 (1.68 undiscounted) years respectively. Total incremental costs 
were US$47,865 (US$80,460 undiscounted). The ICER of belimumab compared to 
standard care was US$59,546 per life year and US$79,407 per QALY gained. Hong 
Kong’s GDP per capita is US$35,961. Thus, this result is within the WHO 
recommended threshold for cost-effectiveness, at 3 times GDP of US$107,883. 
CONCLUSIONS: This study shows that belimumab would be cost-effective 
compared to standard care for the treatment of SLE in Hong Kong.  
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ECONOMIC ASSESSMENT OF RECOMBINANT FACTOR IX IN PROPHYLAXIS FOR 
HEMOPHILIA B IN YOUNG PATIENTS IN MEXICO  
Muciño-Ortega E1, Salinas-Escudero G2, Galindo-Suárez RM1 
1Pfizer S.A. de C.V., Mexico City, Mexico, 2Hospital Infantil de México Federico Gómez, Secretaría 
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OBJECTIVES: Hemophilia B is a rare condition and evidence of specific health 
and economic outcomes for it are relatively scarce. The purpose of this study 
was to assess economic and health consequences of prophylaxis vs on-demand 
supply of factor IX (FIX) in young patients diagnosed with moderate/severe 
hemophilia B, from the perspective of Instituto Mexicano del Seguro Social 
(IMSS). METHODS: A three-state, two-week cycle Markov model followed 
moderate/severe hemophilia B patients starting at age 2 until they reached 18 
years. Patients in prophylaxis received 64.6 IU recombinant FIX/kg per infusion 
and 2.77 infusions every two weeks (same dose used in spontaneous bleeds), 
while patients in the on-demand arm received 69.4 IU plasma-derived FIX/kg to 
manage spontaneous bleeds. A literature review for outcomes in hemophilia B 
was performed (rates of bleeding with prophylaxis and on-demand therapy, 
average doses). Weight and probability of death per age correspond to the 
Mexican population. Avoided bleeds were the effectiveness measure used. The 
model does not consider other costs than FIX acquisition costs and emergency 
room, which were extracted from IMSS´s sources (except the cost of recombinant 
FIX, provided by the manufacturer). Costs are expressed in 2012 US$. Costs and 
consequences were discounted at 5%/annum. Univariate sensitivity analysis was 
performed. RESULTS: The prophylaxis group experienced 49% fewer bleeds than 
the on-demand group (39.11 vs. 83.32 per patient, respectively), however, this is 
reached with an incremental cost of $817,818.89 (cost of prophylaxis was 
$920,411.15, almost nine times the cost of on-demand). In spite of this, ICER for 
prophylaxis was $18,500.63/avoided bleed. The model is highly sensitive to 
probability of spontaneous bleeding, doses and cost of acquisition of FIX. 
CONCLUSIONS: At IMSS, prophylaxis with recombinant FIX for the management 
of patients with moderate/severe hemophilia B would be an intervention with 
strong health benefits worth the additional investment required.  
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ECONOMIC ASSESSMENT OF THE PROPHYLAXIS VERSUS ON-DEMAND 
APPROACH FOR THE TREATMENT OF HEMOPHILIA A IN YOUNG PATIENTS IN 
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OBJECTIVES: Hemophilia A is a disease with extreme disabling consequences. 
Prophylaxis helps to diminish them, but its cost should be assessed. The study 
was intended to estimate the economic and health consequences of prophylaxis 
vs on-demand supply of factor VIII (FVIII) in the management of patients with 
hemophilia A, from the perspective of Instituto Mexicano del Seguro Social 
(IMSS). METHODS: A three-state, two-week cycle Markov model simulated 
hemophilia in children from age 2 to 18 in two arms: prophylaxis with 
recombinant FVIII (25UI moroctocog alfa/kg every other day) and infusions of 
40UI/kg of plasma derived FVIII for spontaneous bleeds. The number of bleeds 
per approach, utilities and infusions required to control spontaneous bleeds 
were extracted from international literature. Both weight per age and probability 
of death were extracted from Mexican sources. Effectiveness measures were 
QALYs and bleeds avoided. The model assumed that safety and effectiveness 
profiles of both types of FVIII are equivalents, with no differences in costs of 
administration or adverse event management. Only the costs of acquisition of 
FVIII and emergency room were considered (both extracted from IMSS sources). 
Both costs and consequences were discounted at 5%/year. The costs are 
expressed in 2012 US$. Univariate sensitivity analysis was performed. RESULTS: 
There were 69% fewer bleeds in the prophylaxis group than in the on-demand 
group (50.7 vs 162.9, respectively), whereas the cost of prophylaxis represented 
5.6 times the cost of on-demand ($730,810 vs. $129,912, respectively), the ICER 
was $5,355.83/avoided bleed. Patients under prophylaxis gained 2.39 QALYs (9.88 
vs. 7.50), with an ICER of $251,876/QALY. The model is very sensitive to 
probability of spontaneous bleeding and dose in prophylaxis. CONCLUSIONS: 
From IMSS´s perspective, prophylaxis with moroctocog alfa for the management 
of patients with hemophilia A would bring highly valuable health benefits to 
patients, but more resources would need to be invested.  
 
PSY44  
COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL THERAPIES FOR THE 
TREATMENT OF MODERATE AND SEVERE PSORIASIS IN INSTITUTIONAL 
MARKET IN ECUADOR  
Torres Toala FG1, Albuja Riofrio MF2, Mould Quevedo JF3, Estévez C4 
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OBJECTIVES: Psoriasis is a chronic skin disease that strongly affects quality of 
life of its patients. In Ecuador, this disease affects 0.59% of the population and is 
estimated that 650 new patients are diagnosed every year with psoriasis 
according to the Ecuadorian National Foundation of Psoriasis. Biologic 
treatments had dramatically changed the therapeutics, outcomes and cost of 
management of these patients. The aim of this study is to assess the cost-
effectiveness of biologic alternatives available in Ecuador to treat moderate to 
severe psoriasis adult patients from a public payer’s perspective. METHODS: A 
decision-tree model was developed to simulate the clinical course of patients 
(18yrs+) treated with etanercept (50mg per week), adalimumab (80 mg on week 0, 
thereafter 40 mg every 2 weeks) and infliximab (5 mg/kg at weeks 0, 2, 6 and 
thereafter every 8 weeks) as first-line therapies, as well as treatment associated 
costs (2-year timeframe with a 5% annual discount rate). Effectiveness measures 
were the percentage of patients reaching 75% improvement using the Psoriasis 
Area and Severity Index (PASI-75) and quality adjusted life years gained (QALY´s). 
Costs considered included: biologic acquisition costs, concomitant medication, 
medical follow-up and side effects management. Clinical response of 
alternatives was extracted from published literature. Unit costs were collected 
from official Ecuadorian databases (Ministry of Health, National Social Security). 
RESULTS: After two years, the percentage of patients reaching PASI-75 were 
59.1%, 62.1% and 62.4% for adalimumab, etanercept and infliximab respectively 
(p=0.077, Friedman test). QALY´s associated to each alternative were: 1.50, 1.53 
and 1.53, respectively. Expected mean costs per patient were: US$ 66,240 for 
adalimumab; US$ 39,585 for etanercept and US$ 49,055.6 for Infliximab. These 
results were supported through probabilistic sensitivity analyses. 
CONCLUSIONS: In Ecuador, the less expensive therapy to treat moderate to 
severe adult psoriasis patients would be etanercept.  
 
PSY45  
COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FOR THE TREATMENT OF 
NEUROPATHIC PAIN IN COLOMBIA  
Ordoñez Molina JE1, Orozco Giraldo JJ1, Gutierrez-Ardila MV2 
1CES University, Medellin, Colombia, 2Pfizer S.A.S., Bogota, Colombia  
OBJECTIVES: Neuropathic pain is caused by various disorders affecting the 
central and peripheral nervous system. Its most common causes are secondary 
to herpes zoster infection and as a complication of diabetes mellitus. The aim of 
this analysis is to evaluate the cost-effectiveness of pregabalin versus duloxetine 
to estimate the pain reduction in diabetic neuropathy and postherpetic neuralgia 
from the social perspective in Colombia. METHODS: A Markov model was 
developed with 3 health-states: improvement (pain reduction >50% using visual 
analogue scale [VAS] against baseline), no improvement and treatment 
discontinuation (due to therapeutic failure). The time horizon is of 5 years (three-
month cycles) and discounts annually effectiveness and costs using a 3% rate. 
Comparators were pregabalin (150-300 mg/day) vs. duloxetine (60 mg/day). 
Population (>18 years) with neurophatic pain was estimated in 775,152 for 
Colombia. Effectiveness and utility data were taken from a literature and meta-
analysis of controlled clinical trials. Costs were taken from official tariff 
manuals, pricing laws and from the local health insurance company SURA. Costs 
are presented in 2012 USD. Effectiveness measure was Quality Adjusted Life 
Years (QALYs). RESULTS: Over a 5-year period, pregabalin obtained 231,105 
QALYs more than duloxetine (1,003,720 and 772,615 QALYs, respectively). Total 
expected savings with pregabalin was USD439.5M compared to duloxetine (total 
expected costs: USD664.8M and USD1,104.4M, respectively); costs for medical 
disabilities (sick leaves) were USD43.8 lower with pregabalin than duloxetine. 
Probabilistic sensitivity analyses showed the robustness of the model. 
CONCLUSIONS: Pregabalin is shown to be a cost-saving alternative compared 
with duloxetine for the treatment of neuropathic pain; pregabalin would have a 
higher rate of patients with reduction pain (51%) than duloxetine (41%), a larger 
number of QALYs and would have savings (USD567.1 per patient) due to lower 
costs of treatment and fewer payments for medical disabilities.  
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COST-UTILITY ANALYSIS OF SPINAL CORD STIMULATION IN PATIENT WITH 
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OBJECTIVES: Failed back surgery syndrome (FBSS) represents one main cause of 
chronic neuropathic or mixed pain. Clinical trials have shown that Spinal Cord 
